Global Biologics Contract Manufacturing Market Research Report 2022

Market Analysis and Insights: Global Biologics Contract Manufacturing Market
Contract manufacturing is a type of outsourcing in which a company enters into an agreement or legal agreement for a product, part or component with another manufacturing company, who then uses that agreement or legal settlement of the product in its production process. This involves the manufacture of biopharmaceutical molecules, proteins, nucleic acids, blood components and vaccines developed from biological sources. These companies specialize in the production of molecules and provide different types of services such as development processes, analysis, and quality control.
The global Biologics Contract Manufacturing market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Monoclonal Antibodies accounting for % of the Biologics Contract Manufacturing global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Medical Company segment is altered to an % CAGR throughout this forecast period.
China Biologics Contract Manufacturing market size is valued at US$ million in 2021, while the North America and Europe Biologics Contract Manufacturing are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Biologics Contract Manufacturing landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biologics Contract Manufacturing market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biologics Contract Manufacturing market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biologics Contract Manufacturing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biologics Contract Manufacturing market.
Global Biologics Contract Manufacturing Scope and Market Size
Biologics Contract Manufacturing market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Biologics Contract Manufacturing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Monoclonal Antibodies
Recombinant Proteins
Vaccines
Molecular Therapy
Others
Segment by Application
Medical Company
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Lonza Group
Samsung Biologics Co., Ltd.
Thermo Fisher Scientific, Inc.
Cambrex Corporation
Siegfried Holding AG
Fujifilm Holding Corporation
AbbVie, Inc.
Boehringer Ingelheim
Recipharm Pharmaceuticals
WuXi Biologics
Catalent, Inc.